Eli Lilly Posts 79.3% Response Rate for Ovarian Cancer Drug

Twenty-three of 29 women with measurable disease responded; the full cohort included 33. Lilly shares fell 2.54% on Oct. 23, before the release early Oct. 24.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.